Analysts Expect Baxter International Inc (BAX) Will Announce Earnings of $0.60 Per Share

Equities research analysts predict that Baxter International Inc (NYSE:BAX) will report earnings per share of $0.60 for the current fiscal quarter, Zacks reports. Six analysts have issued estimates for Baxter International’s earnings, with the highest EPS estimate coming in at $0.63 and the lowest estimate coming in at $0.48. Baxter International posted earnings of $0.58 per share during the same quarter last year, which would indicate a positive year over year growth rate of 3.4%. The business is scheduled to announce its next earnings report on Wednesday, April 25th.

On average, analysts expect that Baxter International will report full-year earnings of $2.74 per share for the current financial year, with EPS estimates ranging from $2.33 to $2.80. For the next year, analysts forecast that the firm will post earnings of $3.09 per share, with EPS estimates ranging from $2.70 to $3.20. Zacks’ EPS averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Baxter International.

Baxter International (NYSE:BAX) last posted its earnings results on Thursday, February 1st. The medical instruments supplier reported $0.64 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.59 by $0.05. The company had revenue of $2.77 billion during the quarter, compared to the consensus estimate of $2.77 billion. Baxter International had a net margin of 6.79% and a return on equity of 15.12%. The firm’s quarterly revenue was up 4.9% on a year-over-year basis. During the same period in the previous year, the firm posted $0.57 earnings per share.

A number of research firms recently issued reports on BAX. BMO Capital Markets boosted their target price on shares of Baxter International from $74.00 to $77.00 and gave the company an “outperform” rating in a research report on Friday, February 2nd. Barclays boosted their target price on shares of Baxter International from $73.00 to $77.00 and gave the company an “overweight” rating in a research report on Friday, February 2nd. Royal Bank of Canada restated a “hold” rating and set a $72.00 target price on shares of Baxter International in a research report on Friday, February 2nd. Zacks Investment Research upgraded shares of Baxter International from a “sell” rating to a “hold” rating in a research report on Thursday, January 4th. Finally, Raymond James Financial upgraded shares of Baxter International from a “market perform” rating to an “outperform” rating and set a $73.00 target price for the company in a research report on Wednesday, January 3rd. Seven analysts have rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $70.36.

Baxter International (NYSE:BAX) remained flat at $$66.03 during midday trading on Friday. 664,746 shares of the company’s stock were exchanged, compared to its average volume of 3,495,832. The company has a market capitalization of $35,980.00, a price-to-earnings ratio of 50.71, a P/E/G ratio of 1.86 and a beta of 0.78. Baxter International has a fifty-two week low of $49.01 and a fifty-two week high of $72.58. The company has a quick ratio of 2.22, a current ratio of 2.80 and a debt-to-equity ratio of 0.37.

In other Baxter International news, SVP Jeanne K. Mason sold 33,350 shares of the company’s stock in a transaction dated Monday, December 4th. The shares were sold at an average price of $65.25, for a total value of $2,176,087.50. Following the completion of the transaction, the senior vice president now owns 124,609 shares in the company, valued at $8,130,737.25. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, SVP Giuseppe Accogli sold 28,641 shares of the company’s stock in a transaction dated Tuesday, January 2nd. The stock was sold at an average price of $67.00, for a total transaction of $1,918,947.00. The disclosure for this sale can be found here. Corporate insiders own 0.05% of the company’s stock.

Several hedge funds have recently added to or reduced their stakes in the company. Endurant Capital Management LP increased its stake in shares of Baxter International by 142.2% during the fourth quarter. Endurant Capital Management LP now owns 50,249 shares of the medical instruments supplier’s stock worth $3,248,000 after purchasing an additional 29,500 shares in the last quarter. Newport Wealth Strategies Inc. purchased a new stake in shares of Baxter International during the fourth quarter worth about $226,000. Biltmore Family Office LLC purchased a new stake in shares of Baxter International during the fourth quarter worth about $382,000. Ladenburg Thalmann Financial Services Inc. increased its stake in shares of Baxter International by 6.2% during the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 51,061 shares of the medical instruments supplier’s stock worth $3,310,000 after purchasing an additional 3,003 shares in the last quarter. Finally, TIAA CREF Investment Management LLC increased its stake in shares of Baxter International by 0.5% during the fourth quarter. TIAA CREF Investment Management LLC now owns 3,654,214 shares of the medical instruments supplier’s stock worth $236,208,000 after purchasing an additional 19,093 shares in the last quarter. 83.12% of the stock is owned by institutional investors and hedge funds.

WARNING: This news story was originally published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this news story on another publication, it was illegally copied and republished in violation of U.S. & international copyright and trademark law. The original version of this news story can be read at https://www.chaffeybreeze.com/2018/02/15/analysts-expect-baxter-international-inc-bax-will-announce-earnings-of-0-60-per-share.html.

Baxter International Company Profile

Baxter International Inc, through its subsidiaries, provides renal and hospital products. The Company operates through two segments: Hospital Products and Renal. Its Hospital Products business manufactures sterile intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, parenteral nutrition therapies, infusion pumps, inhalation anesthetics and biosurgery products.

Get a free copy of the Zacks research report on Baxter International (BAX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Baxter International (NYSE:BAX)

Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply